학술논문
359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S394-S395
Subject
Language
ISSN
0923-7534